Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study

Abstract

Purpose: In preclinical models, established molecular determinants of cellular sensitivity to cyclophosphamide, long a mainstay of chemotherapeutic regimens used to treat breast cancers, include the aldehyde dehydrogenases that catalyze the detoxification of this agent, namely, ALDH1A1 and ALDH3A1. As judged by bulk quantification of relevant catalytic… (More)
DOI: 10.1007/s00280-001-0412-4

Topics

11 Figures and Tables

Cite this paper

@article{Sldek2002CellularLO, title={Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study}, author={Norman E. Sl{\'a}dek and Rahn E. Kollander and Lakshmaiah Sreerama and David T. Kiang}, journal={Cancer Chemotherapy and Pharmacology}, year={2002}, volume={49}, pages={309-321} }